---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084095"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2026-07-16T12:35:13+00:00"
generated_at: "2026-07-16T12:40:42.964892+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences preannounces record Q2 revenue of ~$261M, CFO steps down

## Summary
- Preliminary Q2 2026 WAKIX net revenue ~$261M, record quarter, up 30% YoY and 21% QoQ.
- Reaffirms full-year 2026 net revenue guidance of $1.0B-$1.04B.
- CFO Glenn Reicin steps down effective July 16, 2026 to pursue other opportunities.
- Stephen Mollichella, SVP and Controller, appointed Interim Principal Financial Officer.
- Full Q2 results to be reported on August 4, 2026.

## SEC filing metadata
- accession: 0001104659-26-084095
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2026-07-16T12:35:13+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/0001104659-26-084095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084095
- JSON: https://secwatch.observer/filing/0001104659-26-084095.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084095.txt

## Key facts
- Executive change
  Glenn Reicin departed as Chief Financial Officer at Harmony Biosciences Holdings, Inc..
  - Action: stepping down
  - Role: Chief Financial Officer
  source text: On July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/0001104659-26-084095-index.htm
- Executive change
  Stephen Mollichella was appointed as Interim Principal Financial Officer at Harmony Biosciences Holdings, Inc..
  - Action: appointed
  - Role: Interim Principal Financial Officer
  source text: On July 16, 2026, the Board of Directors of the Company appointed Stephen Mollichella, the Company’s Senior Vice President and Controller, as Interim Principal Financial Officer of the Company, effective as of July 16, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/0001104659-26-084095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.